EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY.

Q4 Medicine
Georgian medical news Pub Date : 2025-03-01
H-T Bi, Y Wang, T-T Wang
{"title":"EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY.","authors":"H-T Bi, Y Wang, T-T Wang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic retinopathy (DR) remains a leading global cause of blindness, significantly affecting the quality of life of patients with diabetes. This clinical observational study was designed to comprehensively assess the synergistic effects of anti-vascular endothelial growth factor (anti-VEGF) drugs and panretinal photocoagulation (PRP) on the progression of DR and visual outcomes. A total of 120 patients with severe non-proliferative or proliferative DR were prospectively recruited and randomly assigned into two groups: the combination therapy group (anti-VEGF + PRP) and the PRP monotherapy group. The results clearly demonstrated that the combination group achieved remarkable anatomical and functional improvements, with a more substantial reduction in macular edema and neovascularization. Long-term follow-up over 24 months further revealed better visual acuity retention and a lower incidence of complications in the combination group. These findings strongly support the integration of anti-VEGF agents into traditional PRP protocols for the effective management of advanced DR.</p>","PeriodicalId":12610,"journal":{"name":"Georgian medical news","volume":" 360","pages":"6-8"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgian medical news","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetic retinopathy (DR) remains a leading global cause of blindness, significantly affecting the quality of life of patients with diabetes. This clinical observational study was designed to comprehensively assess the synergistic effects of anti-vascular endothelial growth factor (anti-VEGF) drugs and panretinal photocoagulation (PRP) on the progression of DR and visual outcomes. A total of 120 patients with severe non-proliferative or proliferative DR were prospectively recruited and randomly assigned into two groups: the combination therapy group (anti-VEGF + PRP) and the PRP monotherapy group. The results clearly demonstrated that the combination group achieved remarkable anatomical and functional improvements, with a more substantial reduction in macular edema and neovascularization. Long-term follow-up over 24 months further revealed better visual acuity retention and a lower incidence of complications in the combination group. These findings strongly support the integration of anti-VEGF agents into traditional PRP protocols for the effective management of advanced DR.

抗vegf药物联合全视网膜光凝治疗糖尿病视网膜病变的疗效及预后:临床观察研究。
糖尿病视网膜病变(DR)仍然是全球失明的主要原因,严重影响糖尿病患者的生活质量。本临床观察性研究旨在综合评估抗血管内皮生长因子(anti-VEGF)药物和全视网膜光凝(PRP)对DR进展和视力结果的协同作用。前瞻性招募120例严重非增殖性或增殖性DR患者,随机分为两组:联合治疗组(抗vegf + PRP)和PRP单药治疗组。结果清楚地表明,联合组在解剖和功能上取得了显著的改善,黄斑水肿和新生血管的减少更为显著。长期随访24个月后发现,联合用药组视力保持较好,并发症发生率较低。这些发现有力地支持将抗vegf药物整合到传统的PRP方案中,以有效地管理晚期DR。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Georgian medical news
Georgian medical news Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
207
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信